ExodusPoint Capital Management’s Avalo Therapeutics AVTX Stock Holding History

ExodusPoint Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$265K	Sell	17,751 -14,516	-45%	-$227K	﹤0.01%	1337
2025 Q4	$586K	Buy	+32,267	New	+$545K	﹤0.01%	1151
2022 Q1	–	Sell	-4	Closed	-$18K	–	2185
2021 Q4	$18K	Buy	+4	New	+$24K	﹤0.01%	2085
2019 Q2	–	Sell	-5	Closed	-$77K	–	1094
2019 Q1	$77K	Buy	+5	New	+$74.8K	0.01%	623

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ExodusPoint Capital Management's AVTX Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Avalo Therapeutics (AVTX) stake by 45% in Q1 2026, selling an estimated $227K and leaving 17,751 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #1337.

ExodusPoint Capital Management first reported a position in AVTX in Q1 2019 and has held it in 4 quarters since. The position peaked at $586K in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

ExodusPoint Capital Management held 17,751 shares of Avalo Therapeutics worth $265K as of Q1 2026.
ExodusPoint Capital Management sold 14,516 Avalo Therapeutics shares in Q1 2026, an estimated $227K.
Avalo Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1337 holding.
ExodusPoint Capital Management first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 4 quarters since.
ExodusPoint Capital Management's Avalo Therapeutics position peaked at $586K in Q4 2025.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.